How does ICE Bioscience reduce IP and know-how risks when sponsors transfer proprietary compounds and assay designs?

ICE Bioscience builds discovery campaigns on internal platform technologies, including ICESTP Safety Panels and ICECP and KRAS cancer cell panels, which reduces the need for sponsors to transfer proprietary assay architectures or cell assets. ICESTP uses predefined target sets aligned with Bowes-44 and Safety-77 literature, and ICECP uses an internal bank of more than 600 tumor cell lines, over 100 engineered and resistant lines, and more than 500 human tumor cell lines for panel construction.

How does ICE Bioscience address assay reproducibility and false-positive or false-negative risk?

ICESTP Safety Panels 44 and 77 are functional secondary pharmacology panels run in both single-concentration and full dose–response modes with potency estimation. All kinase targets are profiled at 1 mM ATP, and reports include radar plots and concentration–effect curves, allowing sponsors to evaluate consistency and confirm pharmacology across targets.

How does ICE Bioscience support raw data transparency and secondary pharmacology data integrity?

ICESTP outputs include full dose–response data, numerical effect tables, and graphical plots for each target, giving sponsors visibility from primary response values through to IC50 or EC50 metrics. The panels are aligned with published Bowes-44 and Safety-77 recommendations, which provide an external reference for target selection and data structure.

How does ICE Bioscience limit variability in high-throughput screening compared with manual offshore setups?

ICE Bioscience operates a joint automated laboratory with SPT Labtech in Beijing that integrates firefly liquid handling into high-throughput screening and assay development workflows. Firefly supports non-contact positive displacement dispensing over nanoliter to milliliter ranges in 96-well and 384-well formats and is used for 2D and 3D viability, clonogenic, and panel assays, reducing operator and plate-to-plate variability.

How does ICE Bioscience align safety pharmacology services with Western regulatory expectations?

ICESTP Safety Panel 44 is described as aligned with historical Bowes-44 off-target selection and ICH expectations, and ICESTP Safety Panel 77 is described as aligned with the industry Safety-77 framework for secondary pharmacology. The ICESTP Drug Abuse Safety Panel follows FDA recommendations for assessing drug abuse potential with 55 CNS targets and 101 assays.

Join us at the 10th Annual FTD Forum - Events

Join us at the 10th Annual FTD Forum

DATE:2026-04-08

AI is reshaping drug discovery, but translating it into real progress requires the right preclinical tools. That's where ICE Bioscience comes in.

We will be participating in the 10th Annual FTD Forum 2026, hosted by SABPA (Socal Association For Biomedical and Pharmaceutical Advancements).

This year's theme highlights the transformative impact of AI across drug discovery, advanced therapeutics, and precision diagnostics — a perfect match for our commitment to accelerating AI-driven therapeutic innovation and precision medicine development.

Join us as we explore how AI is revolutionizing the biotech landscape. This is an excellent opportunity to connect, learn, and contribute to the future of healthcare innovation!

Date: April 17, 2026

Location: Hilton San Diego/Del Mar, CA

PREV：ICE Bioscience to Attend the AACR 2026 A...

NEXT：There's no more

RELEVANT NEWS

ICE Bioscience to Attend the A...
2026-03-26
ICE Bioscience to Attend the 2...
2026-03-17
ICE Bioscience to Attend the S...
2026-03-10
ICE Bioscience to Exhibit at W...
2026-02-01

Contact Us

We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.

Target Based Assays

Cell Based Assays

Featured Services

In Vitro Safety Assessment

In Vitro Immunology Assays

In Vivo Pharmacology

DMPK

NEWS

Join us at the 10th Annual FTD Forum

RELEVANT NEWS

Contact Us